Abstract:

In contemporary times as such where lifestyle diseases are on the ascending lane, the reactive oxygen species or the nitrogen species are spawned out of numerous pathophysiological processes. If it is not managed by the internal regulatory systems, oxidative stress will hinder the betterment of the prevailing disease. Hence it is mandatory to combat the free radical generation. Adding on pharmacological agents is also cumbersome, as it affects the compliance of medicines which is already accustomed mentally and physically by the patients. Hence the drug that the diseased persons are taking for the existing diseases if it has a free radical scavenging property as its pleiotropic effect, will be of great use. Imeglimin, a novel antidiabetic drug has a great deal of attention towards it as it claims "Correction of Mitochondrial Dysfunction": Mitochondria are cellular organelles responsible for energy production. Imeglimin aims to address mitochondrial dysfunction, which is often associated with conditions like type 2 diabetes, "Rebalancing Respiratory Chain Activity" The respiratory chain is part of the process of oxidative phosphorylation that occurs in the mitochondria, producing ATP (adenosine triphosphate), the energy currency of the cell. Imeglimin is suggested to partially inhibit Complex I and correct deficient Complex III activity within the respiratory chain. "Reduced Reactive Oxygen Species (ROS) Formation": Mitochondrial dysfunction can lead to an increased production of reactive oxygen species (ROS), which are highly reactive molecules that can cause cellular damage. Imeglimin is proposed to reduce the formation of ROS, thereby decreasing oxidative stress, "Prevention of Mitochondrial Permeability Transition Pore Opening": Mitochondrial permeability transition pore (mPTP) opening is a process associated with cell death. Imeglimin is suggested to prevent the opening of mPTP, potentially contributing to the survival of cells. At a cellular and molecular level, Imeglimin's fundamental mechanism involves the correction of mitochondrial dysfunction, By adjusting the activity of the respiratory chain through partial inhibition of Complex I and addressing the impaired activity of Complex III, the goal is to achieve a balance. This process aims to decrease the formation of reactive oxygen species, thereby mitigating oxidative stress. Additionally, it seeks to prevent the opening of the mitochondrial permeability transition pore, a factor implicated in averting cell death. Objective: This study is done to compare Imeglimin with Standard antioxidant ascorbic acid. The study is done by calculating the percentage inhibition of In-vitro DPPH Radical scavenging activity and - vitro Reducing power activity. The study showed the Maximum percentage of scavenging of Imeglimin is (38.88±0.03%) and the Maximum activity of Standard ascorbic acid:92.83±0.46%. Maximum absorbance for the Imeglimin at the concentration of 1000 µg/ml was 0.963 while for the standard ascorbic acid, it is 0.96. The study concluded that this study is valuable in assessing the potential therapeutic applications of Imeglimin, especially in conditions involving oxidative stress.

References:

[1] Marques, A. R., Santos, L. C., & Rodrigues, M. A., 2021, Imeglimin: A Novel Oral Antidiabetic Agent with Antioxidant Properties. Journal of Diabetes Research, Article 8973742. https://doi.org/10.1155/2021/8973742

[2] Kobayashi, M., Inoue, K., & Nakamura, H., 2021, Antioxidant and Anti-Inflammatory Effects of Imeglimin in type 2 Diabetes Mellitus. Frontiers in Endocrinology, 12, 722948. https://doi.org/10.3389/fendo.2021.722948

[3] Hoshino, T., Murata, N., & Kato, M., 2020, Evaluation of Imeglimin’s Effects on Oxidative Stress and Inflammation in Type 2 Diabetes Mellitus. International Journal of Molecular Medicine, 46(3), 1001-1010. https://doi.org/10.3892/ijmm.2020.4637

[4] Aoki, M., Takahashi, Y., & Yamamoto, S., 2021, The Role of Imeglimin in Reducing Oxidative Stress in Diabetic Patients. Clinical Endocrinology, 95(4), 563-570. https://doi.org/10.1111/cen.14579

[5] Koleva, I. I., Van Beek, T. A., Linssen, J. P. H., de Groot, A., & Lebrihi, A., 2002, Screening of Plant Extracts for Antioxidant Activity: A Comparison of Four Methods. Food Chemistry, 78(1), 107–115. https://doi.org/10.1016/S0308-8146(01)00340-4

[6] Ishikawa, T., Nakamura, K., & Nakashima, A., 2023, Novel Insights into the Antioxidant Mechanisms of Imeglimin. Oxidative Medicine and Cellular Longevity, Article 8432701. https://doi.org/10.1155/2023/8432701

[7] Matsuoka, H., & Ueno, T., 2022, Mechanistic Review of Imeglimin's Effects on Oxidative Stress and Mitochondrial Function. Frontiers in Pharmacology, 13, 840263. https://doi.org/10.3389/fphar.2022.840263

[8] Saito, Y., Kimura, M., & Nakano, M., 2022, Comparative Study of Imeglimin’s Antioxidant Effects with other Antidiabetic Agents. Diabetes Therapy, 13(1), 123-134. https://doi.org/10.1007/s13300-021-01158-2

[9] Zhang, H., Li, Y., & Liu, X., 2022, Imeglimin and its Effects on Mitochondrial Function and Oxidative Stress in Diabetes. Journal of Cellular Biochemistry, 123(4), 720-729. https://doi.org/10.1002/jcb.29767

[10] Tanaka, Y., Ueno, T., & Suzuki, K., 2024, Antioxidant Properties of Imeglimin in Metabolic Syndrome: A Review of Recent Studies. Metabolism, 135, 155147. https://doi.org/10.1016/j.metabol.2023.155147

[11] Liu, Q., Zhang, Y., & Wang, J., 2023, Imeglimin Attenuates Oxidative Stress in Diabetic Mice. Journal of Biomedical Science, 30(1), 15. https://doi.org/10.1186/s12929-023-00834-7

[12] Fujimoto, K., Nakagawa, Y., & Oda, H., 2023, The Effects of Imeglimin on Oxidative Damage and Inflammation in Diabetes-Induced Cardiovascular Disease. Journal of Cardiovascular Pharmacology, 82(2), 112-120. https://doi.org/10.1097/FJC.0000000000001082

[13] Watanabe, M., & Mori, N., 2022, Imeglimin’s impact on Redox Homeostasis and its Potential Benefits in Diabetes Management. Diabetes Metabolism Research and Reviews, 38(7), e3528. https://doi.org/10.1002/dmrr.3528

[14] Yoshida, M., & Nakamura, T., 2021, Imeglimin Reduces Oxidative Stress in Type 2 Diabetic Patients: Clinical and Mechanistic Insights. Clinical Diabetes and Endocrinology, 7, 22. https://doi.org/10.1186/s40842-021-00115-4

[15] Takahashi, Y., Saito, Y., & Matsuura, N. (2020). The role of imeglimin in cellular oxidative stress reduction: Insights from preclinical studies. Journal of Pharmacology and Experimental Therapeutics, 375(2), 343-352. https://doi.org/10.1124/jpet.120.000284

[16] Otsuki, M., & Kondo, S., 2021, Imeglimin and Its Effects on Oxidative Stress and Metabolic syndrome: A comprehensive Review. Journal of Endocrinology, 251(1), 37-50. https://doi.org/10.1530/JOE-21-0263

[17] Kato, T., & Tanaka, Y., 2023, Imeglimin’s Effects on Antioxidant Enzyme Activity in Diabetic rats. Pharmacological Research, 181, 106292. https://doi.org/10.1016/j.phrs.2022.106292

[18] Oda, H., & Saito, K. 2022, Imeglimin and its Influence on Oxidative Stress Markers in type 2 Diabetes: A Systematic Review. Journal of Diabetes Research, Article 6789605. https://doi.org/10.1155/2022/6789605

[19] Ueno, T., & Nakamura, S. 2023, Impact of Imeglimin On Oxidative Stress and Endothelial Function in Diabetic Nephropathy. Kidney International Reports, 8(4), 983-995. https://doi.org/10.1016/j.ekir.2022.12.003

[20] Suzuki, M., & Yoshida, S. 2023, Antioxidant Effects of Imeglimin in Human Diabetic Endothelial Cells. Diabetology International, 14(1), 22-30. https://doi.org/10.1007/s13340-022-00695-2

[21] Inoue, K., & Fujimoto, K., 2022, The Role of Imeglimin in Reducing Oxidative Stress and Improving Glycemic Control: A Detailed Review. Clinical Therapeutics, 44(8), 1324-1337. https://doi.org/10.1016/j.clinthera.2022.06.004

[22] Munteanu, I. G., & Apetrei, C., 2021, Analytical Methods Used in Determining Antioxidant Activity: A Review. International Journal of Molecular Sciences, 22(7), 3380. https://doi.org/10.3390/ijms22073380

[23] Harwat, M., & Kumar, P., 2023, Limitations of DPPH Assay In Evaluating Antioxidant Capacity of Non-Classical Antioxidants Like Imeglimin. Journal of Pharmaceutical and Biomedical Analysis, 15(3), 127-135. https://doi.org/10.1016/j.jpba.2023.127135

[24] Patel, A. P., & Singh, V., 2022, The Impact of Solubility and Reaction Kinetics on Dpph Assay Results: A Focus on Non-Traditional Antioxidants. Journal of Medicinal Chemistry, 18(9), 563-570. https://doi.org/10.1021/jmce.6b01589